{"id":"W4281640394","doi":"10.1056/nejmoa2203690","title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","year":2022,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":2548,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Daiichi Sankyo Europe; National Cancer Institute; First Hospital of Jilin University; West China Hospital, Sichuan University; University of California, San Francisco; Kyungpook National University; Fundació Institut de Recerca Hospital Universitari Vall d’Hebron; Peking Union Medical College; Cleveland Clinic; Samsung; Universitat de Barcelona; Seoul National University Hospital; College of Medicine, Seoul National University; Memorial Sloan-Kettering Cancer Center; Yonsei University; Chinese Academy of Medical Sciences; Tel Aviv University; Seoul National University; Jilin University; Liaoning Cancer Hospital and Institute; Sichuan University; Sun Yat-sen University; Queen Mary University of London; Cleveland Clinic Foundation; University of Ulsan; Institute of Genetics; AstraZeneca; Cancer Research Institute","keywords":"Trastuzumab; Breast cancer; Medicine; Oncology; Internal medicine; Cancer","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null}